CLAIMS

1. Use of Ras homologue enriched in brain (Rheb) in the manufacture of a medicament for the treatment or prevention of Huntington's disease (HD), wherein the Rheb is constitutively active Rheb mutant (caRheb; S16H).

2. The use of Rheb according to claim 1, wherein the subject may have mitochondrial dysfunction, aberrant cholesterol homeostasis, striatal atrophy, impaired dopamine signaling and/or decreased autophagy.

3. Use of Ras homologue enriched in brain (Rheb) in the manufacture of a medicament for the treatment of mHTT-associated metabolic phenotypes and/or reversal of striatal atrophy, wherein the Rheb is constitutively active Rheb mutant (caRheb; S16H).

4. The use of the Rheb according to any one of claims 1-3, wherein the Rheb is contained in a viral vector.

5. The use of the Rheb according to claim 4, wherein the viral vector is an adeno-associated viral (AAV) vector.

6. The use of the Rheb according to claim 5, wherein the AAV is AAV1, AAV2, AAV5, AAV6 and/or AAV9.

7. The use of the Rheb according to claim 6, wherein the AAV is AAV2.

8. The use of the Rheb according to claim 6, wherein the AAV is AAV2/1.

9. The use of the Rheb according to any one of claims 1-8, wherein the Rheb is to be administered to the brain of the subject either directly or via the bloodstream.

10. The use of the Rheb according to claim 9, wherein the Rheb is to be administered to the subject's striatum, cortex or ventricular space.

11. The use of the Rheb according to any one of claims 1-10, wherein the subject is human.

12. The use of the Rheb according to any one of claims 1-11, wherein the Rheb is to be injected at 1-5 locations in the CNS.

13. The use of the Rheb according to claim 12, wherein the Rheb is to be injected at a single location in the brain.